EP1589996A4 - Anti-integrin alpha beta 3 antibody formulat ions and uses thereof - Google Patents

Anti-integrin alpha beta 3 antibody formulat ions and uses thereof

Info

Publication number
EP1589996A4
EP1589996A4 EP04707034A EP04707034A EP1589996A4 EP 1589996 A4 EP1589996 A4 EP 1589996A4 EP 04707034 A EP04707034 A EP 04707034A EP 04707034 A EP04707034 A EP 04707034A EP 1589996 A4 EP1589996 A4 EP 1589996A4
Authority
EP
European Patent Office
Prior art keywords
antibody
integrin alpha
alpha beta
formulat ions
formulat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04707034A
Other languages
German (de)
French (fr)
Other versions
EP1589996A2 (en
Inventor
Christian B Allan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP1589996A2 publication Critical patent/EP1589996A2/en
Publication of EP1589996A4 publication Critical patent/EP1589996A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP04707034A 2003-01-30 2004-01-30 Anti-integrin alpha beta 3 antibody formulat ions and uses thereof Withdrawn EP1589996A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44377703P 2003-01-30 2003-01-30
US44381003P 2003-01-30 2003-01-30
US443777P 2003-01-30
US443810P 2003-01-30
PCT/US2004/002701 WO2004066957A2 (en) 2003-01-30 2004-01-30 ANTI-INTEGRIN ανβ3 ANTIBODY FORMULATIONS AND USES THEREOF

Publications (2)

Publication Number Publication Date
EP1589996A2 EP1589996A2 (en) 2005-11-02
EP1589996A4 true EP1589996A4 (en) 2009-01-21

Family

ID=32829839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04707034A Withdrawn EP1589996A4 (en) 2003-01-30 2004-01-30 Anti-integrin alpha beta 3 antibody formulat ions and uses thereof

Country Status (5)

Country Link
EP (1) EP1589996A4 (en)
JP (1) JP2006516636A (en)
AU (1) AU2004207003A1 (en)
CA (1) CA2512174A1 (en)
WO (1) WO2004066957A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
CA2615122A1 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP2359834B1 (en) 2006-03-15 2016-11-09 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
SI2061810T1 (en) 2006-09-05 2015-04-30 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
MX2009003982A (en) 2006-10-20 2009-04-27 Amgen Inc Stable polypeptide formulations.
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
MX2009010361A (en) 2007-03-29 2009-10-16 Abbott Lab Crystalline anti-human il-12 antibodies.
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2197970B1 (en) * 2007-10-09 2011-07-20 Hercules Incorporated Crosslinkercontaining adhesive compositions
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
JP5808349B2 (en) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー Biomarkers for theranosis
JP2013528570A (en) * 2010-03-31 2013-07-11 ユニベルシテ ドゥ ジュネーブ Stabilized antibody preparations and uses thereof
KR20130043104A (en) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 Circulating biomarkers for disease
US10316095B2 (en) * 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
ES2964713T3 (en) 2014-10-23 2024-04-09 Amgen Inc Reduction of the viscosity of pharmaceutical formulations
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
JP7377596B2 (en) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド Low viscosity, high concentration evolocumab formulations and their manufacturing method
EP3884962A1 (en) 2017-12-01 2021-09-29 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2020060183A1 (en) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 Liquid formation for stabilizing trastuzumab antibody
JP7317379B2 (en) * 2019-01-04 2023-07-31 国立大学法人京都大学 Examination method for ulcerative colitis and primary sclerosing cholangitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016645A1 (en) * 1997-01-30 2001-08-23 Ixsys, Incorporated Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
WO2002013860A1 (en) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016645A1 (en) * 1997-01-30 2001-08-23 Ixsys, Incorporated Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
WO2002013860A1 (en) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
EP1314437A1 (en) * 2000-08-11 2003-05-28 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations

Also Published As

Publication number Publication date
WO2004066957A3 (en) 2005-04-07
WO2004066957A2 (en) 2004-08-12
JP2006516636A (en) 2006-07-06
EP1589996A2 (en) 2005-11-02
AU2004207003A1 (en) 2004-08-12
CA2512174A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
EP1589996A4 (en) Anti-integrin alpha beta 3 antibody formulat ions and uses thereof
IL174637A0 (en) Fibrosis-inducing agents, compositions containing the same and medical implants containing the same
IL173299A (en) 2,4-pyrimidinediamine compounds, compositions containing them and their use
EP1539941A4 (en) Adzymes and uses thereof
PT1736541E (en) Novel modified galectin 9 protein and use thereof
AU2003295402A8 (en) Acyl guanidine compounds and use thereof
EP1767634A4 (en) Novel galectin 8 modification protein and use thereof
AU2003296369A8 (en) Imminoamines and preparation thereof
AU2003215257A8 (en) Modified defensins and their use
AU2003231827A8 (en) Pseudo-tissues and uses thereof
EP1582586A4 (en) Apoptosis-associated protein and use thereof
GB0227906D0 (en) Compounds and their use
EP1577322A4 (en) Novel proteins and use thereof
EP1541677A4 (en) Novel proteins and use thereof
GB0230134D0 (en) Compounds and their use
GB0230281D0 (en) Compounds and their use
GB0317864D0 (en) Compounds and their use
FR2859108B1 (en) ANTI-STRESS COMPOSITION AND INHALER
AU2003216442A8 (en) Enkurin and uses thereof
EP1699809A4 (en) Amniotic-derived peptide and uses thereof
GB2420345B (en) 3-alpha-glycosyl alpha, alpha-trehaloses their preparation and use
GB0321300D0 (en) Protein structure and uses thereof
GB0228538D0 (en) Protein structure and uses thereof
GB0311166D0 (en) Composition and use
GB0325241D0 (en) Composition and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050816

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20081219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090318